ClinicalTrials.gg
CompletedNCT06747247Updated Feb 6, 2026

A Clinical Study Evaluating the Safety, Tolerability, and Efficacy of MT1013 in Hemodialysis Subjects With Secondary Hyperparathyroidism

A Phase 2 interventional study of Long-term Dosing Cohort and Single ascending doses of MT1013 in Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis, sponsored by Shaanxi Micot Pharmaceutical Technology Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-02-06.

Sponsored by Shaanxi Micot Pharmaceutical Technology Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 8 months after the study started (first participant enrolled Apr 2023, registered Dec 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Hyperparathyroidism, Secondary with a site in China — 4 open to participants now, 5 under way, 1 of them phase 3. Hyperparathyroidism, Secondary · China.

Enrollment
11th of 18
98 · median 158
Started
2023
with 3 others
Phase 2
5 of 23
1 open now
Registered
18th of 23
by date
Lead sponsor
4 of 23
Shaanxi Micot Pharmaceutical Technology Co., Ltd.

Among the 23 studies in Hyperparathyroidism, Secondary with a site in China, this one is the 11th largest by enrollment of the 18 interventional ones that give a count, is one of 4 that started in 2023, is one of 5 in phase 2, and was the 18th registered.

Hyperparathyroidism, Secondary

188 studies on the registry are indexed under Hyperparathyroidism, Secondary; 15 are open to participants now.

Browse Hyperparathyroidism, Secondary studies →

Open to participants now

4 of the 23 studies in Hyperparathyroidism, Secondary with a site in China are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 10 Hyperparathyroidism, Secondary studies recruiting now, 5 (50%) set no upper age limit and 4 (40%) stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Hyperparathyroidism, Secondary with a site in China, or all of them as a file.
02

Study summary

A multicenter, Phase II, randomized, double-blind, single ascending dose (SAD) and multiple ascending dose (MAD), as well as single-arm clinical study evaluating the long-term efficacy and safety of MT1013 in hemodialysis subjects with secondary hyperparathyroidism. The SAD study consists of five cohorts at doses of 5, 10, 20, 40, and 60 mg. The MAD study consists of three cohorts at doses of 5, 10, and 20 mg. In both the SAD and MAD studies, each cohort includes 8 subjects (6 subjects receive the active investigational drug, and 2 subjects receive matching placebo), and the cohorts are conducted sequentially. In the long-term dosing cohort, all subjects will undergo regular hemodialysis three times per week, receiving the drug once after each hemodialysis session for a total duration of 52 weeks

03

Conditions studied

  • Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria (Subjects must meet all of the following criteria to participate in the trial):

  1. Male or non- pregnant, non-lactating female aged 18 to 80;
  2. The patient has been on stable, adequate hemodialysis treatment for >3 months prior to screening;
  3. Intact parathyroid hormone (iPTH) level of at least 300 pg/mL;
  4. Serum calcium (corrected serum calcium if albumin \<40 g/L) ≥2.25 mmol/L (9.0mg/dL);
  5. ≥ 8.0 g/dL;
  6. Subject is clinically stable, as judged by medical history, physical examination, and routine laboratory tests, apart from chronic renal failure;
  7. Able to understand and willing to sign the written form;
  8. Women of must have a negative pregnancy test result prior to enrollment, or be for at least 1 year, or be permanently sterile(i.e., documented hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) for ≥6 weeks. Fertile men with partners of childbearing potential and women of childbearing potential must use effective (i.e., any combination of two of the following: male or female condom with spermicidal gel,diaphragm, sponge, or cervical cap with spermicidal gel) from signing the informed consent until 90 days after MT1013 infusion.

Postmenopausal is defined as:

Age ≥55 years \& amenorrhea for ≥12 months;

Or Age \<55 years but no spontaneous menses for at least 2 years;

Or Age \<55 years with spontaneous menses within the past 1 year, but currently amenorrheic, and with postmenopausal gonadotropin levels (luteinizing hormone and follicle-stimulating hormone levels >40 IU/L) or postmenopausal estradiol levels (\<5.3 pmol/L or 5 ng/dL) or meeting the laboratory's definition of "postmenopausal range";Having undergone bilateral oophorectomy.

Exclusion Criteria (Subjects meeting any of the following criteria will be excluded from the study):

1 .History of severe ventricular arrhythmia or symptomatic ventricular arrhythmia at screening, or >470 ms for males or >480 ms for females at screening;

2. Subjects with heart failure symptoms,class III or IV by (NYHA) , at screening;

3. History of myocardial infarction, coronary angioplasty, or coronary artery bypass graft within the past 6 months;

4. History of seizures or having received treatment for seizures;

5. Prior parathyroidectomy;

6. Serum transaminases (, aspartate aminotransferase) >3 times the at screening; or serum albumin \<30 g/L;

7.History of organ transplant (excluding being on the kidney transplant waiting list), hematopoietic stem cell transplant, or bone marrow transplant; or patients planning to undergo organ transplantation;

8.Severe uncontrolled hypertension, defined as systolic blood pressure >180 mmHg and diastolic blood pressure >100 mmHg despite optimal medical therapy before enrollment;

9.Known or other comorbidities with a of \<3 months (except for patients disease-free for ≥5 years, or disease-free for ≥5 years after the last dose of chemotherapy );

10.Known alcohol or illicit drug abuse within 12 months prior to screening, unwillingness or inability to abstain from alcohol for 24 hours prior to each study visit, or unwillingness or inability to limit alcohol consumption to a maximum of 2 drinks per day during the study (one drink is equivalent to 360 mL of regular beer, 150 mL of wine, or 45 mL of 40% alcohol spirits);

11.Positive for (HIV) or known diagnosis of acquired immunodeficiency syndrome (AIDS) at screening;

12.Subjects positive for surface antigen (HBsAg) at screening (indicative of chronic hepatitis B) AND with serum transaminases (alanine aminotransferase, aspartate aminotransferase) >2 times the upper limit of normal;

13.Positive for virus ribonucleic acid (RNA) by polymerase chain reaction (PCR) at screening (indicative of active hepatitis C - usually screened via hepatitis C antibody [HCV-Ab], with PCR for HCV RNA if HCV-Ab positive);

14.Patients with known to the product and/or its components;

15.Patients who have participated in another clinical trial and received an investigational drug within 8 weeks prior to the first dose or within 5 half-lives of the investigational drug (whichever is longer);

16. Patients who have previously received MT1013;

17. Subjects who have received cinacalcet treatment within 8 days prior to the first dose;

18. Pregnant or potentially pregnant women or lactating women;

19. Inability to fully comply with the study protocol;

20.Any other medical or psychiatric condition that, in the investigator's opinion, precludes participation in the study;

21. Subjects with active gastrointestinal bleeding or a high risk of astrointestinal bleeding tendency at screening.

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
98 participants (actual)

Study arms

  • Experimental
    MT1013 for SAD

    Single ascending doses of MT1013

    Drug: Single ascending doses of MT1013

  • Placebo comparator
    Placebo for SAD

    Placebo comparator for SAD

    Drug: Single ascending doses of MT1013

  • Experimental
    MT1013 for MAD

    Multiple ascending doses of MT1013

    Drug: Multiple ascending doses of MT1013

  • Placebo comparator
    Placebo for MAD

    Placebo comparator for MAD

    Drug: Multiple ascending doses of MT1013

  • Experimental
    Long-term Dosing Cohort

    Dose titration period covers the first 10 weeks , followed by maintenance dosing period, for a total treatment duration of 52 weeks

    Drug: Long-term Dosing Cohort

Interventions

  • DrugLong-term Dosing Cohort

    All subjects will undergo regular hemodialysis three times per week. Administration of MT1013occurs once after each hemodialysis session and will continue for 52 weeks. The first 10 weeks constitute the dose-titration period, during which the drug dose is titrated every 3 weeks based on iPTH and serum corrected calcium levels. During the maintenance dosing period, doses is adjusted based on iPTH and serum corrected calcium levels.

  • DrugSingle ascending doses of MT1013

    All subjects will receive a single dose (MT1013 or placebo) only after a single hemodialysis session

  • DrugMultiple ascending doses of MT1013

    All subjects will undergo hemodialysis three times per week. Dosing (MT1013 or placebo) will occur once after each hemodialysis session, continuing for either 2 or 4 weeks (treatment period).

06

What researchers measure

Primary outcomes

  1. SAD/MAD :Percentage of treatment-emergent adverse events (TEAEs)

    To investigate the safety and tolerability of MT1013 by assessing the incidence and severity of TEAEs in Single Ascending Dose (SAD Cohort) and Multiple Ascending Doses (MAD Cohort)

    Time frame: SAD:on Day 8±1. MAD:on Day 16+2 or 30+2 and Day 21±2 or 35±2

  2. Long-term Dosing Cohort: Proportion of subjects with > 30% reduction in serum iPTH compared to baseline level.

    Proportion of subjects achieving a \>30% reduction in serum iPTH from baseline at Week 14.

    Time frame: 14 weeks

Secondary outcomes

  1. Change in the mean serum intact parathyroid hormone (iPTH) from baseline

    Change in serum intact parathyroid hormone (iPTH) from baseline at each visit

    Time frame: SAD:on Day 8±1. MAD:on Day 16+2 or 30+2 and Day 21±2 or 35±2. Long-term Dosing Cohort: 52 weeks

  2. Proportion of subjects achieving a >30% reduction in serum iPTH from baseline

    Proportion of subjects achieving a \>30% reduction in serum iPTH from baseline at each visit

    Time frame: SAD:on Day 8±1. MAD:on Day 16+2 or 30+2 and Day 21±2 or 35±2. Long-term Dosing Cohort: 52 weeks

  3. Change from baseline in corrected Ca

    Change in corrected calcium from baseline at each visit

    Time frame: SAD:on Day 8±1. MAD:on Day 16+2 or 30+2 and Day 21±2 or 35±2. Long-term Dosing Cohort: 52 weeks

  4. Change from baseline in ionized calcium

    Change in ionized calcium from baseline at each visit

    Time frame: SAD:on Day 8±1. MAD:on Day 16+2 or 30+2 and Day 21±2 or 35±2

  5. Change in DXA-measured bone mineral density (BMD) at the femoral neck and lumbar spine from baseline

    Change in DXA-measured bone mineral density (BMD) at the femoral neck and lumbar spine from baseline at each visit

    Time frame: Long-term Dosing Cohort: 52 weeks

  6. Incidence and severity of treatment-emergent adverse events (TEAEs)

    Incidence and severity of adverse events occurred during the study period

    Time frame: Long-term Dosing Cohort: 52 weeks

  7. Change from baseline in serum phosphorus

    Change in serum phosphorus from baseline at each visit

    Time frame: SAD:on Day 8±1. MAD:on Day 16+2 or 30+2 and Day 21±2 or 35±2

  8. Change from baseline in the mean corrected calcium-phosphorus product

    Change in the mean corrected calcium-phosphorus product from baseline at each visit

    Time frame: SAD:on Day 8±1. MAD:on Day 16+2 or 30+2 and Day 21±2 or 35±2

  9. Assessment change of Bone Turnover Markers - Change from Baseline

    Change in PINP from baseline at each visit

    Time frame: SAD:on Day 8±1. MAD:on Day 16+2 or 30+2 and Day 21±2 or 35±2. Long-term Dosing Cohort: 52 weeks

  10. Assessment change of Bone Turnover Markers - Change from Baseline

    Change in CTX from baseline at each visit

    Time frame: SAD:on Day 8±1. MAD:on Day 16+2 or 30+2 and Day 21±2 or 35±2. Long-term Dosing Cohort: 52 weeks

  11. Assessment change of Bone Turnover Markers - Change from Baseline

    Change in OC from baseline at each visit

    Time frame: SAD:on Day 8±1. MAD:on Day 16+2 or 30+2 and Day 21±2 or 35±2. Long-term Dosing Cohort: 52 weeks

  12. Assessment change of Bone Turnover Markers - Change from Baseline

    Change in b-ALP from baseline at each visit

    Time frame: SAD:on Day 8±1. MAD:on Day 16+2 or 30+2 and Day 21±2 or 35±2. Long-term Dosing Cohort: 52 weeks

  13. Assessment change of Bone Turnover Markers - Change from Baseline

    Change in TRAP-5b from baseline at each visit

    Time frame: SAD:on Day 8±1. MAD:on Day 16+2 or 30+2 and Day 21±2 or 35±2. Long-term Dosing Cohort: 52 weeks

  14. Cmax of MT1013

    Cmax - Maximum plasma concentration

    Time frame: SAD:on Day 8±1. MAD:on Day 16+2 or 30+2 and Day 21±2 or 35±2

  15. Tmax of MT1013

    Tmax - Time to reach Cmax

    Time frame: SAD:on Day 8±1. MAD:on Day 16+2 or 30+2 and Day 21±2 or 35±2

  16. T1/2 of MT1013

    T1/2 - Elimination half-life

    Time frame: SAD:on Day 8±1. MAD:on Day 16+2 or 30+2 and Day 21±2 or 35±2

  17. AUC0-tau of MT1013

    AUC0-tau - Area under the plasma concentration-time curve during one dosing interval

    Time frame: SAD:on Day 8±1. MAD:on Day 16+2 or 30+2 and Day 21±2 or 35±2

  18. AUC0-t of MT1013

    AUC0-t - Area under the plasma concentration-time curve from time zero to the last measurable concentration

    Time frame: SAD:on Day 8±1. MAD:on Day 16+2 or 30+2 and Day 21±2 or 35±2

07

Study locations

1 site
  • First Affiliated Hospital College of Medicine, Zhejiang University
    Hangzhou, Zhejiang 310003, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2023 to primary completion in May 2025, 25 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2024
First posted
Dec 24, 2024
StartActual
Apr 7, 2023
Primary completionActual
May 12, 2025
CompletionActual
May 12, 2025
Last update
Feb 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06747247
Lead sponsor
Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Responsible party
Sponsor
First posted
Dec 24, 2024
Start date
Apr 7, 2023
Primary completion
May 12, 2025
Completion
May 12, 2025
Last update
Feb 6, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion